If you have been living with depression, there is a good chance you are familiar with SSRIs and SNRIs — medications like sertraline (Zoloft), escitalopram (Lexapro), fluoxetine (Prozac), or venlafaxine (Effexor). These drugs have been the backbone of depression treatment for over three decades, and they help millions of people. But they do not help everyone, and the limitations of traditional antidepressants are significant enough that many patients and clinicians are looking for alternatives.
Ketamine therapy represents the most significant departure from conventional antidepressant pharmacology in a generation. Understanding how these approaches differ — in mechanism, timeline, efficacy, and experience — can help you make an informed decision about your treatment options.
How SSRIs and SNRIs Work
Traditional antidepressants operate on the monoamine hypothesis of depression: the idea that depression results from insufficient levels of serotonin (and sometimes norepinephrine) in the brain. SSRIs block the reabsorption of serotonin in the synaptic cleft, making more serotonin available to neighboring neurons. SNRIs do the same for both serotonin and norepinephrine.
This mechanism is indirect. Increasing serotonin availability in the synapse is only the first step. The actual therapeutic effects are believed to come from downstream changes in gene expression, receptor sensitivity, and eventually, modest improvements in neural plasticity. This cascade of secondary effects is why SSRIs take 4 to 6 weeks to produce noticeable clinical improvement — and sometimes longer.
The Failure Rate Problem
The STAR*D trial, the largest clinical study of antidepressant efficacy ever conducted, found that only about one-third of patients achieved remission with their first SSRI. After trying a second medication, cumulative remission rates improved but still left a substantial number of patients without adequate relief. After four sequential medication trials, approximately 30% of patients remained treatment-resistant.
These are not small numbers. Treatment-resistant depression (TRD) — formally defined as depression that has not responded to two or more adequate antidepressant trials — affects an estimated 2.8 million adults in the United States alone.
How Ketamine Works Differently
Ketamine bypasses the serotonin system entirely. Instead, it targets the glutamate system — the brain's primary excitatory neurotransmitter network. By blocking NMDA receptors on inhibitory interneurons, ketamine triggers a surge of glutamate that activates AMPA receptors, leading to rapid release of BDNF (brain-derived neurotrophic factor) and activation of the mTOR signaling pathway.
The result is synaptogenesis: the formation of new synaptic connections in the prefrontal cortex and hippocampus within hours. This is a fundamentally different biological process from the slow, indirect modulation of serotonin levels that SSRIs provide.
Side-by-Side Comparison
| Factor | SSRIs / SNRIs | IV Ketamine |
|---|---|---|
| Primary Mechanism | Serotonin reuptake inhibition | NMDA blockade → AMPA activation → synaptogenesis |
| Neurotransmitter System | Serotonin (and norepinephrine for SNRIs) | Glutamate |
| Onset of Action | 4–6 weeks | Hours to days |
| Response Rate (TRD) | 10–30% (after prior failures) | 60–72% |
| Administration | Daily oral pill | IV infusion, 40–60 min per session |
| Treatment Protocol | Daily, ongoing (months to years) | 6 infusions over 2–3 weeks, then maintenance |
| Common Side Effects | Nausea, weight gain, sexual dysfunction, fatigue, emotional blunting | Temporary dissociation, nausea, dizziness (resolve within 1–2 hours post-infusion) |
| Anti-Suicidal Effects | Gradual (weeks); black box warning in young adults | Rapid (hours); demonstrated in multiple clinical trials |
| Dependency Risk | Discontinuation syndrome when stopping | Low at clinical doses; administered in supervised setting |
| Setting | Home (prescription) | Clinical setting with medical monitoring |
What Is Treatment-Resistant Depression?
If you have tried two or more antidepressant medications at adequate doses for adequate durations (typically 6–8 weeks each) without achieving satisfactory improvement, you meet the clinical definition of treatment-resistant depression. This does not mean your depression is untreatable — it means the serotonin-based approach has not been sufficient for your particular neurobiology.
TRD is not a reflection of willpower, compliance, or effort. Depression is a neurobiological condition, and different brains respond to different mechanisms of action. For many TRD patients, the glutamate-based mechanism of ketamine provides the pathway to improvement that serotonin modulation could not.
When to Consider Ketamine Therapy
Ketamine therapy is generally recommended when:
- You have not responded adequately to two or more conventional antidepressant trials
- You are experiencing severe depression with active suicidal ideation that requires rapid intervention
- Side effects from traditional antidepressants are intolerable (sexual dysfunction, weight gain, emotional blunting)
- You need a bridge therapy while waiting for a new medication to take effect
- Your depression co-occurs with anxiety, PTSD, or OCD, conditions where ketamine has also shown efficacy
Ketamine is not typically recommended as a first-line treatment for mild to moderate depression in patients who have never tried conventional antidepressants. The standard approach of starting with SSRIs or therapy remains appropriate for most initial presentations.
Can You Combine Treatments?
Yes. Ketamine therapy does not require you to stop your current medications. In fact, most patients at LUMUS continue their existing antidepressant regimen during and after ketamine treatment. The two approaches work through independent neurotransmitter systems and do not produce harmful interactions in the vast majority of cases.
Many clinicians view ketamine as complementary rather than competitive with existing treatments. Ketamine provides rapid relief and enhanced neural plasticity, while SSRIs and psychotherapy support long-term stability. The combination can be more effective than either approach alone.
Your prescribing physician and our clinical team will review your full medication list during the screening process to ensure safety and identify any specific considerations for your situation.
Making an Informed Decision
The choice between continuing traditional antidepressants and exploring ketamine therapy is a personal and clinical one. There is no single right answer for every patient. What matters is having accurate information about how each approach works, what the evidence shows, and what you can realistically expect.
If you are living with depression that has not responded to conventional treatment, or if you want to understand whether ketamine therapy might be appropriate for your situation, we are here to help. Our free 15-minute screening consultations provide a no-pressure opportunity to ask questions and discuss your specific circumstances with a clinical professional.